AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Overview
The pharmaceutical industry is shifting as legacy blockbusters lose patent protection. Investors must choose between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) as they navigate drug pricing reforms and evolving pipelines.
AbbVie has successfully diversified its portfolio beyond its historic blockbuster Humira, while Pfizer is aggressively deploying capital from its pandemic-era windfall into new oncology and obesity treatments. Both companies are cornerstones of many income-focused portfolios, yet they offer distinct risk profiles for those seeking healthcare exposure.
Details
According to its latest annual report, AbbVie focuses on high-growth therapeutic areas like immunology, neuroscience, and aesthetics within the pharmaceutical stocks universe. Its recent growth is driven largely by two key immunology drugs which together represented nearly 42% of its revenue in 2025. The company distributes its products through major wholesalers including McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH), and Cencora Inc (NYSE:COR). Customer concentration like this adds a layer of risk to the business.
Source
Originally published at www.fool.com.